bluebird bio Inc (NASDAQ:BLUE) will outline today key activities underway intended to advance the company’s LentiGlobin programs in transfusion-dependent β-thalassemia (TDT) and severe …
Maxim analyst Jason McCarthy is out with a research report on shares of bluebird bio Inc (NASDAQ:BLUE) discussing the aftermath of Mast Therapeutics’ (NYSEMKT:MSTX) …
bluebird bio Inc (NASDAQ:BLUE) announced the signing of a strategic research and development collaboration and licensing agreement encompassing T cell receptor (TCR) immunotherapies …
Jefferies analysts are diving into the latest biotech news, with Gilead Sciences, Inc. (NASDAQ:GILD) and bluebird bio Inc (NASDAQ:BLUE) on opposite ends of the spectrum.
bluebird bio Inc (NASDAQ:BLUE) announced that theEuropean Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for LentiGlobin drug product in …
Maxim analyst Jason McCarthy weighed in with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the gene-therapy-product maker announced that a pivotal phase III study …
bluebird bio Inc (NASDAQ:BLUE) has initiated a Phase III trial (HB-207) for its pipeline drug LentiGlobin, designed to treat transfusion-dependent beta-thalassemia patients with …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, …
Piper Jaffray reduced the price target to $95, while reiterating Overweight
Leerink Swann analyst, Michael Schmidt, reiterates his Outperform rating on bluebird bio Inc (NASDAQ:BLUE) after the company reported its 2Q16 financial results. The analyst couples his …
